Skip to content

Endomicroscopic Evaluation of Food-induced Gastrointestinal Mucosal Alteration

A Multicenter Ambispective Evaluation of Atypical Food Allergies In-vivo Utilizing Confocal Laser Endomicroscopy in Pediatric and Adult Patients

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06792838
Enrollment
200
Registered
2025-01-27
Start date
2025-03-31
Completion date
2034-09-30
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Allergy, Irritable Bowel Syndrome

Brief summary

The overarching goal of this study is to establish a first ever registry in the U.S. to collect outcomes data to evaluate changes in the gastrointestinal (GI) mucosa following direct food application utilizing Confocal Laser Endomicroscopy (CLE). This will be assessed in pediatric and adult patients who present to the outpatient clinic with persistent irritable bowel syndrome-like symptoms while testing negative for celiac disease and have either negative or very low/low levels of Immunoglobulin E (IgE) serological tests.

Detailed description

The prevalence of food allergies in children and adults are estimated to be 5-7% and 11% in the US respectively. The mechanism underlying food allergies are either IgE mediated, non-IgE mediated or both. CLE is a diagnostic modality that allows for high-resolution imaging of the GI tract, providing real-time in-vivo visualization of the mucosal and submucosal microstructure similar to histology. What differentiates it from conventional histology wherein tissue is sectioned vertically, is that the endomicroscopic images are a single optical plane parallel to the tissue surface, yielding multiple optical sections of successive depths of greater precision. Recent studies demonstrated the utility of CLE in the evaluation of gastroenterological diseases, specifically for inflammatory bowel disease. Although histological evaluation continues to remain the gold standard, CLE has potential applications in surveillance, targeted biopsies and disease management of GI conditions such as celiac disease, eosinophilic disease and more recently in patients with Irritable Bowel Syndrome (IBS) with atypical food allergies that are non-IgE mediated. A common observation in patients with IBS using CLE include increased epithelial gaps when compared to healthy controls. It is proposed that there is an alteration in the epithelial barrier which in healthy state, prevents the microbes and antigens from entering the body. Increased epithelial cell extrusions result in altered intestinal permeability, which is commonly seen in IBS. The utility of CLE in visualizing the integrity of the intestinal barrier in children with atypical presentation of food allergies is unknown. The ability to observe these dynamic changes in real-time is promising in the management of IBS. Endomicroscopic diagnosis of food-induced allergy-like reactions was first used as a guideline in the implementation of the food intolerance testing performed as part of this protocol.

Interventions

DEVICEConfocal Laser Endomicroscopy

1. The Endo microscope probe will be prepped in channel #1 and normal saline (30 ml) will be flushed into the duodenal mucosa through channel # 2 which will serve as a control. Inject 1-3ml fluorescein 10% intravenously. 2. The duodenal mucosa is assessed at a minimum of four sites (20 seconds each 3. The first potential allergen will be sprayed via catheter onto the mucosa. 4. After 2 minutes, three different areas of of duodenum will be assessed with the gastroflex probe for fluorescein leakage and cell shedding. If fluorescein leakage and cell shedding are visualized that is considered a positive test,no further allergy testing can be conducted. If the first allergen test is negative, irrigate and repeat steps for the next potential allergen for a maximum of three allergens per patient.

Sponsors

University of Nebraska Medical Center and Children's Hospital & Medical Center
CollaboratorUNKNOWN
Stanford University
CollaboratorOTHER
Metrodora Institute
CollaboratorUNKNOWN
Meliora Bio ApS
CollaboratorUNKNOWN
Cook Children's Health Care System
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This study is not an interventional study; however, it uses an FDA approved investigational device.

Eligibility

Sex/Gender
ALL
Age
2 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Patients must meet all of the following criteria to be included in the study * Adults and children presenting with a prolonged history of IBS-like symptoms (as described by Rome IV criteria) related to food intake. * A negative or very low/low levels of Ig-E food allergy panel or negative skin prick test * Negative celiac disease work up

Exclusion criteria

* If patient had a previous Esophagogastroduodenoscopy (EGD) and Colonoscopy with biopsy positive for any chronic inflammatory condition for eg. Inflammatory Bowel Disease (IBD), the patient will be excluded. * Pregnant or nursing at the time of CLE. * Known allergy to fluorescein. * Impaired renal function tests. * Active GI bleeding.

Design outcomes

Primary

MeasureTime frame
Number of subjects with IBS symptoms with evidence of epithelial barrier dysfunctionDay 1

Secondary

MeasureTime frameDescription
Health-Related Quality of Life as Assessed by Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Scale QuestionnaireBaseline, 1 month, 6 months, 12 monthsThe Pediatric Quality of Life Inventory (PedsQL) Questionnaire is an instrument used to measure quality of life in children and adolescents ages 2-18 that can be used by children to self-report or by parents as a proxy. PedsQL Gastrointestinal Symptoms Scales is a specific module of the PedsQL containing 58 items across 10 gastrointestinal symptom scales. Participants rate problems on a scale of 0 (never a problem) to 4 (almost always a problem). Items are reverse-scored and linearly transformed to a 0-100 scale, thus higher scores indicate better GI-specific Health-Related Quality of Life (HRQOL) and hence lower symptoms.

Contacts

Primary ContactSumith Roy, MBBS, MPH
Sumith.Roy@cookchildrens.org682-885-1790
Backup ContactLaurie Bailey, PhD
Laurie.Bailey@cookchildrens.org682-885-6451

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026